For hormone-responsive breast cancer
- Approximately 60% of breast cancers amongst pre-menopausal women are oestrogen-receptor-positive12 and a proportion of these patients may benefit from gonadotropin-releasing hormone (GnRH) agonist therapy
- This approach works by blocking the production of gonadotropins in the pituitary gland which in turn blocks the release of oestrogen (and progesterone) from the ovaries12–14
- With blocked or reduced oestrogen, the oestrogen-receptor-positive breast cancer is inhibited from growing12–14